Prevention of body weight loss and sarcopenia by a novel selective androgen receptor modulator in cancer cachexia models
Megumi Morimoto(Takeda (Japan)), Masuo Yamaoka, Katsuji Aikawa(Takeda (Japan)), Takahito Hara(Takeda (Japan))
Cited by 32
Related Papers
Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
|PubMed|2003|427
Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response
|Proceedings of the National Academy of Sciences|2018|172
Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer
|Bioorganic & Medicinal Chemistry|2011|126
Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys
|The Journal of Steroid Biochemistry and Molecular Biology|2012|116
Androgen Receptor and Invasion in Prostate Cancer
|Cancer Research|2008|115